All news articles for March 2023

Exterior of new German logistics hub © UPS Healthcare

UPS Healthcare opens logistics facility in Germany

By Jane Byrne

UPS Healthcare says its first dedicated healthcare logistics facility in Giessen, Germany is now up and running. Up to 150 jobs have been created as a result of this operation, added the provider.


Building an mRNA giant: Moderna’s 7 priorities for 2023

By Rachel Arthur

mRNA pioneer Moderna wants to grow and thrive past its initial COVID-19 vaccine success. “To continue to build the best version of Moderna, we have established seven priorities for 2023,” says CEO Stephane Bancel: as the company outlines goals that range...


BioNTech and OncoC4 team up on novel checkpoint antibody

By Rachel Arthur

BioNTech and OncoC4 have announced a worldwide license and collaboration agreement to develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications....


Novartis releases long-term Zolgensma data

By Rachel Arthur

Novartis has presented new data which ‘underscore the transformational and sustained benefit’ of spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec): with treated children maintaining motor milestones after 7.5 years.

The extra MHRA funding will help accelerate patient access to new treatments, says the government. Pic: getty/221A

MHRA gets £10m boost from UK government

By Rachel Arthur

The UK Medicines and Healthcare products Regulatory Agency (MHRA) will receive £10m ($12m) in extra government funding over the next two years: targeted at helping the agency adapt post-Brexit and accelerating routes for bringing new medicines onto the...

© GettyImages/ipopba

Urgent action needed to reduce high costs of gene therapies

By Jane Byrne

The extremely high costs of gene therapies are unsustainable, and a global commitment to affordable, equitable access to these treatments is urgently needed, concluded the organising committee of a conference on human genome editing.


Sanofi to acquire Provention Bio for $2.9bn

By Rachel Arthur

Sanofi will acquire US-based Provention Bio: gaining Tzield (teplizumab-mzwv), which was approved by the FDA last year as the first and only therapy to delay the onset of Stage 3 type 1 diabetes.

© GettyImages/Mikhail Makarov

Biosimilars organization hails US legislative effort

By Jane Byrne

The Biosimilars Forum has welcomed a move by US congressman, Richard Hudson, to introduce legislation that would establish a shared savings reimbursement model for biosimilars in Medicare Part B.